CYLD deubiquitinates NEMO

Stable Identifier
R-HSA-741411
Type
Reaction [transition]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

RIP2-induced ubiquitination of NEMO and consequent NFkappaB activation can be reversed in a dose-responsive manner by the deubiquitinase CYLD, suggesting that CYLD negatively regulates RIP2-induced NEMO ubiquitinylation.

Literature References
PubMed ID Title Journal Year
15620648 The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO

Abbott, DW, Wilkins, A, Asara, JM, Cantley, LC

Curr Biol 2004
12917691 The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination

Kovalenko, A, Chable-Bessia, C, Cantarella, G, Israel, A, Wallach, D, Courtois, G

Nature 2003
Participants
Participant Of
Catalyst Activity
Catalyst Activity
Title
Lys63-specific deubiquitinase activity of CYLD [cytosol]
Physical Entity
Activity
Orthologous Events
Authored
Reviewed
Created